The unluckiest drug on Medicare's negotiation list; AstraZeneca bets on a gene therapy workhorse

Taking stock of the drug industry, from the lab to the medicine chest

September 1, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Mark J. Terrill/AP STAT+ | FTC settles with Amgen over $28 billion deal for Horizon The FTC has settled its lawsuit with the pharmaceutical company Amgen over its $28 billion deal for Horizon Therapeutics. By Ed Silverman STAT+ | The curious case of J&J's Stelara, the unluckiest drug on Medicare's list Had the therapy been approved 98 days later, it may not have made the administration's list of drugs subject to price negotiation. By Rachel Cohrs STAT+ | AstraZeneca bets that gene therapy's workhorse will still deliver the goods Seng Cheng moves from Pfizer to champion the adeno-associated virus portfolio and the battle against disease. By Jason Mast Ted S. Warren/AP How a 'weighted lottery' helped underserved patients get a scarce Covid drug "When you give increased odds to people who may be more impacted by a disease, you are not putting any one group in front of the other." By Usha Lee McFarling STAT+ | Humana sues Biden administration over Medicare Advantage audit rule Humana sued the federal government Friday over a rule that claws back overpayments from it and other Medicare Advantage insurers. By Bob Herman STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser